NICE says ‘yes’ to two ovarian cancer drugs, rejects three
27 April 2016 | By Victoria White, Digital Content Producer
The guidance recommends paclitaxel and PLDH for treating ovarian cancer that has returned after previous chemotherapy treatment...
List view / Grid view
News
The global cost of norovirus
26 April 2016 | By Victoria White, Digital Content Producer
Norovirus results in roughly $4.2 billion in health care costs and $60.3 billion in societal costs annually, a new study has found...
Promising top-line results for AZP-531 in Prader-Willi Syndrome
26 April 2016 | By Victoria White, Digital Content Producer
Alizé Pharma has announced top-line results of a Phase II clinical trial of AZP-531 in patients with Prader-Willi Syndrome (PWS)...
EC grants marketing authorisation to Lilly’s ixekizumab
26 April 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Lilly’s ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults...
AstraZeneca and Ironwood sign Zurampic licensing agreement
26 April 2016 | By Victoria White, Digital Content Producer
Under the terms of the agreement, Ironwood Pharmaceuticals will acquire exclusive US rights to Zurampic from AstraZeneca...
Allergan’s $200 million expansion of its Waco facility gets underway
26 April 2016 | By Victoria White, Digital Content Producer
Allergan has broken ground on a $200 million expansion of its Texas Waco facility that will nearly double its current footprint when completed...
Optimising quality and production with Russell Finex sanitary screener
When Enzymatic Therapy stopped outsourcing and built its own FDA-approved manufacturing facility, the goal was to improve product quality, streamline production, and ramp up sales growth. A crucial step was selecting the right pharmaceutical sieving equipment to remove any agglomerates, oversize particles or contaminants from incoming raw dry materials.
FDA grants Breakthrough Therapy Designation to Opdivo in SCCHN
25 April 2016 | By Victoria White, Digital Content Producer
The designation is based on results of a Phase III trial evaluating Opdivo versus investigator’s choice of therapy in patients with SCCHN...
EC grants marketing authorisation for two doses of Gilead’s Descovy
25 April 2016 | By Victoria White, Digital Content Producer
Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients...
The fight against counterfeit medicines
25 April 2016 | By Victoria White, Digital Content Producer
New research is providing the foundation to apply criminology theory to preventing the production and sale of counterfeit medicines...
Trial supports safety and efficacy profile of Pfizer’s varenicline
22 April 2016 | By Victoria White, Digital Content Producer
EAGLES compared the neuropsychiatric safety and efficacy of varenicline and bupropion to placebo and nicotine patch to help people quit smoking...
TPIV 200 and durvalumab to be evaluated in a Phase II ovarian cancer study
22 April 2016 | By Victoria White, Digital Content Producer
TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer...
Daclizumab demonstrates significant improvements in cognition in RRMS
22 April 2016 | By Victoria White, Digital Content Producer
New data demonstrates daclizumab’s positive cognitive outcomes and safety profile in patients with relapsing-remitting multiple sclerosis (RRMS)...
Allergan acquires topical dermatology company Topokine Therapeutics
22 April 2016 | By Victoria White, Digital Content Producer
Allergan has acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development and sales milestones for XAF5...
NICE U-turn on cabazitaxel for prostate cancer
22 April 2016 | By Victoria White, Digital Content Producer
NICE has issued final guidance recommending Sanofi’s Jevtana (cabazitaxel) for some prostate cancer patients...
